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The treatment of disabling intermittent
claudication in patients with superficial femoral
artery occlusive disease—Decision analysis
Brian Nolan, MD, Samuel Finlayson, MD, MPH, Anna Tosteson, ScD, Richard Powell, MD,
and Jack Cronenwett, MD, Lebanon, NH
Objective: To determine the preferred approach to superficial femoral artery (SFA) revascularization of Trans-Atlantic
Inter-Societal Consensus (TASC) B and C lesions in claudicants requiring intervention based on a review of published
data.
Design: Decision analysis, Markov state transition model.
Subjects: Hypothetical cohorts of claudicants with TASC B or TASC C superficial femoral artery lesions considered
candidates for either angioplasty with selective stenting (PTA/S) or greater saphenous vein bypass (GSVB).
Main outcome measure: Quality adjusted life years (QALYs).
Results: For a 65-year-old man with disabling claudication, percutaneous transluminal angioplasty and selective stenting
(PTA/S) was preferred over GSVB for a TASC B SFA lesion. In an otherwise identical patient with a TASC C lesion,
bypass was the preferred therapy. Treating PTA/S failures with subsequent bypass increased the utility of PTA/S but
bypass remained the preferred initial therapy for TASC C lesions. Sensitivity analysis showed that PTA/S surpasses
bypass efficacy for TASC C lesions if PTA/S primary patency is >32% at 5 years, patient age is >80 years, or GSVB
operative mortality is > 6%.
Conclusion: PTA/S is the preferred initial therapy over GSVB for TASC B SFA lesions in patients with disabling
intermittent claudication who require intervention. Given contemporary published outcomes for TASC C lesions, GSVB
is the preferred therapy in operative candidates. In elderly patients or patients at high risk for bypass, PTA/S should be
considered over GSVB. Improved technology that results in a 5-year primary patency of 32% would also justify PTA/S
for TASC C SFA lesions. ( J Vasc Surg 2007;45:1179-84.)Intermittent claudication (IC) resulting from pe-
ripheral artery disease is present in approximately 10% of
the United States population over age 50 and 20% of the
population over age 70.1 Though highly prevalent, the
natural history of IC is relatively benign with deteriora-
tion to critical limb ischemia occurring in 25% to 30%
over five years and amputation in only 1% to 2%.2,3 The
major risk facing patients with IC is mortality from
cardiovascular causes, 30% at 5 years.4,5 Given the rela-
tively low risk of progression and high prevalence of
cardiovascular disease, the initial management of pa-
tients IC has traditionally been conservative and includes
medical therapy (Clopidogrel and statins), life style mod-
ification (smoking cessation and weight loss), and exer-
cise. These measures have been shown in randomized
clinical trials to benefit patients with IC.6 Unfortunately,
compliance is often poor and the impact on functional
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doi:10.1016/j.jvs.2007.02.044capacity is variable.7 Ultimately, a significant percentage
of patients fail conservative therapy.
While relief of IC symptoms is achievable with sur-
gical revascularization, the risks of peripheral bypass are
significant, so typically only severely disabled patients
who fail conservative therapy are considered. The advent
of endovascular therapy, which carries lower procedural
risks, has led to a more aggressive approach to superficial
femoral artery (SFA) revascularization in the claudicant.
In certain practices, percutaneous transluminal angio-
plasty and selective stenting (PTA/S) has consequently
not only replaced bypass as the primary mode of revas-
cularization, but it also challenges conservative measures
as the primary therapy. In 2000, the Trans-Atlantic
Inter-Societal Consensus (TASC) introduced a classifi-
cation system for SFA occlusive disease and proposed
guidelines for its management (Fig 1). Percutaneous
transluminal angioplasty was recommended for TASC A
lesions (short stenosis, 3 cm) and bypass was recom-
mended for TASC D lesions (long occlusions,  5 cm).8
No conclusive recommendation was made for the man-
agement of TASC B (stenosis 3 to 5 cm or occlusions,
3 cm), and C lesions (occlusions 3 to 5 cm or stenosis,
5 cm). The optimal treatment for these lesions remains
a matter of debate and current therapy is largely dictated
by physician preference. To help resolve uncertainty
surrounding the best approach to SFA revascularization
in claudicants, we developed a decision-analytic model
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and short-term risks and benefits of bypass vs PTA/S.
METHODS
A Markov-state transition model was developed using
TreeAge Pro 2006 Suite software (TreeAge Software Inc,
Williamstown, Mass) to simulate hypothetical patient co-
horts (10,000 patients, Monte Carlo simulation) with in-
termittent claudication and SFA occlusive disease (Fig 2).
Three treatment strategies were investigated: femoropopli-
teal bypass, PTA/S, and PTA/S with subsequent femoro-
popliteal bypass for PTA/S failures. Three primary sources
of contemporary data (2000 to 2005) were used to esti-
mate model input parameters including technical success,
procedural risks and patency, health state specific survival,
and quality of life8-10 (Table 1). Outcomes were measured
in quality-adjusted life years (QALYs). Differences were
compared by t-test. To determine the effect of alternative
assumptions, data from a fourth, older source (1994) was
used in sensitivity analysis.11
Health states and model assumptions. The model
transitioned patients between 10 possible health states
based on various input probabilities. The model cycled (in
Fig 1. Trans-Atlantic Inter-Societal Classification (TASC) of
femoro-popliteal occlusive disease.81 year intervals with half-cycle correction) until all patientsin the PTA/S and bypass cohorts were dead based on
expected mortality rates. The cumulative QALYs were tab-
ulated by the software for comparison of the three groups
(PTA/S, GSVB, and GSVB following failed PTA/S). The
model was run for both the treatment of TASC B and C
SFA lesions. To make the model tractable, simplifying
assumptions were made regarding the patients and inter-
ventions. First, all patients had unilateral calf claudication
with either TASC B or C SFA occlusive disease and were
considered candidates for both PTA/S and bypass. Second,
the specific interventions modeled were femoropopliteal
bypass with greater saphenous vein (GSVB) and PTA with
selective (ie, not primary) stenting. Arm vein, synthetic,
composite, or other grafts were not specifically modeled.
Third, the rate of primary graft failure was assumed to be
constant beyond 5 years. Fourth, “assisted patencies” were
based on reported primary assisted and secondary patency
rates from the literature, thus, no distinction was made
between the specific types of, or indications for, reinterven-
tion. Fifth, “failed PTA/S” was defined as occlusion fol-
lowing attempted endovascular revision, thus, patients in
the “GSVB following failed PTA/S” group underwent
bypass following an attempted endovascular reinterven-
tion. Sixth, all patients who failed PTA/S and subsequently
developed critical limb ischemia (CLI) underwent GSVB,
even in the “PTA/S only” cohort. Seventh, patients who
failed GSVB and secondary salvage procedures and subse-
quently developed CLI, underwent amputation. Redo by-
passes were not modeled. Lastly, patients who failed bypass
and bypass salvage and were left with persistent claudica-
tion had no further intervention, unless they subsequently
progressed to critical limb ischemia.
Mortality. A disease specific, excess mortality rate in
claudicants (d) was determined using the declining expo-
nential approximation of life expectancy (DEALE) equa-
tion.12 Briefly, this is defined as the difference between the
mortality of a 65-year-oldmale claudicant and themortality
of an age, sex, race adjusted (ASR) control.5,13 This excess
mortality was assumed to be constant over time and added
Fig 2. Multi-state transition model (Markov process) for treat-
ment of intermittent claudication in patients with SFA occlusive
disease.to the ASRmortality rates for males (race nonspecific) aged
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excess mortality rate in amputees was determined and
added to the ASR mortality rates for the same age cohort.14
Procedural mortality was determined as a weighted average
from the studies referenced above.
Procedural risks. Procedural morbidity was ac-
counted for in the model as a “toll” or reduction in the
cumulative QALYs associated with the specific interven-
tion. This disutility was designated as the average postpro-
cedural recovery time (including complications) and was
deducted from the reward for the first cycle of the Markov
process. Recovery time estimates used in the model were 1
week for PTA/s and 6 or 7 weeks for bypass (Table I).
Procedural patency. Patency definitions were in ac-
cordance with Society for Vascular Surgery standards. Pri-
mary patency implies the maintenance of clinical and he-
modynamic improvement without further intervention.
Primary patency of PTA/S for TASC B and C SFA occlu-
sive disease was determined as a weighted average of con-
temporary studies reporting long-term patency by Kaplan-
Meier life table methodology using the TASC or American
Heart Association (AHA) classification systems.8,10,15 Data
from studies that did not report patency in these formats
were not included. Life table patencies were converted to
annual failure rates using the DEALE equation.12 Similarly,
the primary patency of GSVBwas determined as a weighted
average of the long-term, life table patencies of GSVB in
claudicants reported in a large meta-analysis and a large,
contemporary, multicenter registry.11,16 Although the pri-
Table I. Procedure and patient related input variables
Variable
Quality of life
Claudication
Amputation
Life expectancy
Age
Procedural mortality
PTA/S
GSVB
Amputation
Technical success
GSVB
PTA/S TASC B
PTA/S TASC C
Convalescence (weeks)
PTA/S and PTA/S revision
GSVB for claudication
GSVB for critical limb ischemia
Primary patency
GSVB 1, 2, 3, 4, 5-year 
PTA/S TASC B 1, 2, 3, 4, 5-year 
PTA/S TASC C 1, 2, 3, 4, 5-year 
Assisted Patency
PTA/S
GSVB
Progression to CLI
PTA/S failure
GSVB failuremary patencies modeled for both PTA/S and GSVB overthe first five cycles (5 years) were taken from the literature,
there is little or no data on longer life-time primary patency
rates, particularly with PTA/S. Given this lack of data,
GSVB and PTA/S failure rates beyond 5 years were as-
sumed to take place at a constant rate (assumption 3). The
primary patency rates for PTA/S and GSVB used in the
model are listed in Table I.
“Assisted patency” as defined in the model was calcu-
lated using published primary assisted and secondary pa-
tency rates. For the purpose of the model, no distinction is
made between type of reintervention ( PTA vs PTA/S vs
interposition grafting vs patch angioplasty) or the indica-
tion for reintervention (symptomatic and asymptomatic
restenosis with or without hemodynamic changes). In or-
der to adjust for poorer patencies following multiple revi-
sions, secondary patencies rates were decreased by 25% for
both PTA/S and bypass for these scenarios. This adjust-
ment factor is not explicitly defined in the literature but is
supported based on long-term follow-up data of bypass
grafts and angioplasties which require revision.17,18
Quality of life. Health state utilities were determined
as a weighted average of quality of life studies using the
Nottingham Health Profile (NHP). While quality of life in
patients with chronic lower extremity ischemia has been
studied using many different assessment tools, the NHP
was chosen because it is the most widely used in published
studies on this topic over the past 10 years. The utility of the
claudication health state in the model was determined
using both cohort and case control designed studies (ie,
Base case Range
0.44 0.20–0.75
0.14 *
14.0-yr *
65-yr 65–100
0.5% 0–2%
2% 1–10%
17% 5–40%
95% 70–99%
95% 90–99%
70% 50–90%
1 *
6 *
7 *
85, 80, 75, 70, 65% 5-yr: 80%
82, 70, 63, 55, 55% 5-yr: 70%
65, 30, 15, 15, 15% 5-yr: 40%
40% 30–70%
70% 50–90%
50% 40–70%
10% 5–25%claudicants vs ASR controls, and claudicants pre- and
JOURNAL OF VASCULAR SURGERY
June 20071182 Nolan et alpostrevascularization).2,19-21 Sensitivity analysis was per-
formed to a lower utility limit calculated from studies in
patients with critical limb ischemia. The utility of the am-
putation health state was determined from studies on the
quality of life with major lower extremity (above and below
knee) amputation.14,22
Base case. The base case in the model is a 65-year-old,
male (race nonspecific) with unilateral, intermittent calf
claudication, and either TASC B or C SFA occlusive dis-
ease. His quality of life is 44% of controls. His life expect-
ancy is 14.0 years and his operative mortality is 2%. His
recovery from GSVB is 6 weeks if performed for claudica-
tion, 7 weeks if performed for CLI. His recovery from
PTA/S is 1 week. These data are listed in Table I along with
the procedural patencies.
RESULTS
In the base case, PTA/S was the preferred initial ther-
apy for a TASC B SFA lesion (4.7 QALYs for PTA/S alone
and 5.0 QALYs for PTA/S followed by GSVB for failures,
vs 4.4 QALYs for GSVB alone). In an otherwise identical
patient with a TASC C lesion, GSVB was the preferred
initial therapy (4.4 vs 4.0 QALYs for PTA/S alone and 4.2
QALYs for PTA/S followed by GSVB for failures)(Table
II). A threshold analysis (tornado diagram) was used to
investigate the expected QALYs over a range of values and
to identify variables containing thresholds which would
shift the preferred therapy for TASC C lesions. Thresholds
included PTA/S primary patency, patient age, GSVB op-
erative risk and technical success, the probability of devel-
oping critical limb ischemia following GSVB and PTA/S
failure, and baseline (claudication) quality of life. By one-
way sensitivity analyses, the threshold values at which
PTA/S would surpass bypass for TASC C lesions were
determined (Table III). For very elderly patients (age 80
years) and patients with exceedingly poor baseline quality
of life (27% of control) PTA/S was preferred over GSVB
as initial therapy. Similarly, in high risk patients (6%
predicted operative mortality) and patients with a low
probability of technical success with GSVB (73%),
PTA/S was preferred for TASC C lesions. The probability
of a failed procedure leading to critical limb ischemia (ie,
Table II. Results of Markov decision model Monte
Carlo simulation (10,000 patients) by management
strategy (PTA/S alone, PTA/S  GSVB, GSVB alone)
for TASC B and C lesions. All differences statistically
significant (p  0.001, t-test)
Classification
Claudication Management Strategy Results
(mean QALYs and 95% C.I.)
TASC PTA/S alone
PTA/S 
GSVB GSVB alone
B 4.7 (4.7–4.8) 5.0 (4.9–5.0) 4.4 (4.3–4.4)
C 4.0 (3.9–4.0) 4.2 (4.1–4.2) 4.4 (4.3–4.4)the chance of making them worse than baseline) also con-tained a threshold. For failed PTA/S the threshold was
20% and for failed GSVB the threshold was22%. Two-
way sensitivity analysis of PTA/S vs GSVB 5-year primary
patency was performed. For the base case GSVB 5-year
primary patency of 65%, the 5-year primary patency at
which PTA/S would surpass bypass as the preferred strat-
egy for a TASC C lesion was 32%. The 5-year primary
patencies at which PTA/S would surpass bypass for TASC
C lesions over a range of GSVB patencies are listed in Fig 3.
DISCUSSION
Decision analysis has previously been applied to revas-
cularization for femoropopliteal disease by Hunink et al in
1995.23 The analysis found that PTA was the preferred
initial therapy in claudicants with SFA disease not classified
by TASC. Using data stratified by TASC classification, our
analysis suggests GSVB is the preferred strategy for the
initial management of TASC C lesions in younger patients
with a reasonable operative risk. Although the findings
seem contradictory, the discrepancy is likely the result of
stratification of the primary patency input parameters. Pa-
tency data (for both PTA/S and GSVB) in the Hunink
model were obtained by a large meta-analysis of series
reporting femoropopliteal revascularizations between 1985
and 1993.11 At the time these series and meta-analysis were
Table III. Threshold values for primary PTA/S of TASC
C SFA lesions
Variable Base case Threshold
Quality of life with claudication 44%* 27%*
Age 65 80
Operative mortality (GSVB) 2% 6%
CLI with PTA/S failure 50% 20%
CLI with GSVB failure 10% 22%
Technical success GSVB 95% 73%
5-yr primary patency, PTA/S 15% 32%
*Relative to age matched controls without claudication
Fig 3. Five year GSVB primary patency and corresponding
PTA/S 5-year primary patency threshold for TASC C SFA lesions.published, there were no TASC criteria for the reporting of
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analysis reported patencies based on whether the treated
lesions were either a “stenosis” or an “occlusion”. The
TASC classifications stratify SFA disease into four catego-
ries. Although all TASC A lesions are stenosis and all TASC
D are occlusions, considerable overlap exists between
TASC B and C lesions with regards to stenosis and occlu-
sion (TASC B up to 3 cm occlusion, 3 to 5 cm stenosis;
TASC C 3 to 5 cm occlusions, 5 cm stenosis).8 Classify-
ing SFA lesions as simply “stenoses” or “occlusions”
would, thus, mix TASC B and C lesions and possibly
improve the observed results in the “occlusion” group
relative to the TASC C group in the current study. Using
the patency input parameters in the Hunink model, the
current analysis yields the same results. PTA/S would be
the preferred strategy for both TASC B and C lesions
lending between-model validation to our analysis. Our
model can also be validated externally using the TASC data
and recommendations for the treatment of A andD lesions.
Inputting the reported patencies from the TASC review in
the current model, PTA/S is favored for TASC A lesions
and bypass for TASC D lesions which coincides with the
recommendations of the work group.
Our model predicts that the management of TASC C
SFA lesions with GSVB would provide the greatest quality
adjusted life year benefit in relatively young, healthy pa-
tients. Using sensitivity analysis, thresholds at which this
benefit is lost were determined. Not surprisingly, themodel
determined that patients with high operative mortality
(6%) would benefit from PTA/S rather than GSVB.
Although mortality rates in published series following in-
frainguinal bypass even in patients with critical limb isch-
emia are less than 5%, these reports are of selected patients.
There is a large population of claudicants who are refused
surgery because they are considered a prohibitive operative
risk and who may benefit from PTA/S. Similarly, the
analysis found that in patients greater than 80 years of age,
PTA/S for TASC C lesions was favored. Though not
previously reported, 80 years, in our analysis, is the thresh-
old at which patients on average are not likely to live long
enough to realize a clinically significant durability benefit of
bypass.
The utility of the health states used in this model were
derived from published data on quality of life determined
using the NHP. Although the NHP is not a previously
validated measure in decision analysis, precise health state
utilities have not been reported in these groups of patients
(claudicants, critical limb ischemia patients, and amputees).
The values obtained using NHP published data are exter-
nally validated by the utility values used in the study by
Hunink et al, which were obtained by polling vascular
surgeons.23 The utility of the claudication health state (a
marker for severity of IC) contained a threshold at 0.27
(27% of control). Based on previous reports on quality of
life, this level of disability approximates patients with criti-
cal limb ischemia.2,21 From a modeling standpoint, the
threshold occurred because utility of the claudication state
approximated critical limb ischemia, at which point allpatients in the PTA/S arm of the model are treated with
bypass. Therefore, in patients with extremely severe claudi-
cation with borderline rest pain, a strategy of PTA/S with
subsequent referral for bypass after failed PTA/S may be
preferred although further studies are required for verifica-
tion.
Through the use of a two-way sensitivity analysis of
odds ratios for 5-year primary patency (GSVB vs PTA/S), a
threshold of 32% was determined at which PTA/S would
surpass GSVB benefit for primary therapy of TASC C
lesions. This is a useful target for the advancement of
endovascular therapy and represents an approximate two-
fold improvement in currently published outcomes. Given
the large and increasing number of endovascular therapies,
eg, cryoplasty, LASER atherectomy, mechanical atherec-
tomy, primary stenting, and stent grafting, all with very
limited data on long term patency, we chose to restrict the
endovascular arm of this analysis to the therapy with the
most widely published and accepted data, namely PTAwith
selective stenting. In “real life”, however, the use of alter-
native technologies is common-place and most practitio-
ners who use them do so because of their bias that the
outcomes are better than with PTA alone. While this may
be the case, definitive data is lacking and according to our
model, the goal for these therapies would be to provide a
5-year primary patency of 32% to justify their use vs bypass
for TASC C SFA lesions.
Another threshold variable was the likelihood of devel-
oping critical limb ischemia following GSVB or PTA/S
occlusion. Of note, this refers specifically to the group of
patients whose bypass or PTA/S failed and could not be
successfully revised. There are no precise data on progres-
sion to CLI following PTA/S failure on which to base the
model. It was assumed that since PTA/S failure would
mean occlusion of the native artery, where as for bypass
occlusion the native artery should be unaffected, that pro-
gression to critical ischemia would be higher for failed
PTA/S. Though the validity of the percentage used in the
base case (50%) for progression to critical ischemia after
failed PTA/S may be argued, the threshold at which
PTA/Swould be favored over bypass occurred at 20%. This
appears to be an unlikely scenario since this is only slightly
higher than the base case for GSVB failure (10%). It is
possible, however, that with improvement in technology
that may be achievable and, thus, increase the applicability
of PTA/S.
There are limitations to any decision analysis study.
Decision analysis models are hypothetical and based on
probabilities from published data. The current model is
based on data from large case series since no level I evidence
is available. Case series are subject to selection bias, thus,
these data may not truly represent all claudicants with
TASC B or C SFA lesions. Furthermore, many assumptions
must be made about a patient’s clinical course to simplify
the model so that it will function. Although, the scenarios
modeled approximate “real life”, there is variability which is
not accounted for in the model, eg, redo bypasses, arm vein
bypass, PTA/S of the native artery after failed bypass, or
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PTA/S. Nonetheless, claudicants are encountered on a
daily basis in practice and decisions must bemade regarding
their treatment. This model represents a synthesis of con-
temporary data to help guide these decisions given the lack
of a prospective randomized study.
The advent of minimally invasive, less morbid endovas-
cular techniques has led to a more aggressive approach
toward the treatment of claudication. As these technologies
evolve, there is an increasing ability and willingness to treat
complex SFA lesions despite limited data on long-term
outcomes. Using a decision analytic model, we have inves-
tigated surgical and endovascular treatment strategies for
TASC B and C SFA lesions in patients with disabling IC.
Using data from contemporary literature, our findings sug-
gest that in patients who are relatively young and reason-
able operative candidates, percutaneous transluminal an-
gioplasty with selective stenting is the preferred initial
therapy for TASC B lesions while bypass with greater
saphenous vein is preferred therapy for TASC C lesions.
Bypass following PTA/S failure increases the utility of
primary PTA/S, however, in the case of TASC C lesions,
bypass remains the preferred initial treatment. For patients
greater than 80 years of age or who are at high risk for
surgery, PTA/S should be considered as primary therapy.
For PTA/S to supplant bypass as primary therapy for TASC
C lesions in all patients, an improvement in 5-year primary
patency to 32% is necessary.
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